The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Background Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality
among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized …

Respiratory syncytial virus (RSV) is a cause of severe respiratory illness in older adults. In
May 2023, the Food and Drug Administration approved the first vaccines for prevention of …

Background Vaccination against respiratory syncytial virus (RSV) during pregnancy may
protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F …

Abstract On June 21, 2023, CDC's Advisory Committee on Immunization Practices
recommended respiratory syncytial virus (RSV) vaccination for adults aged≥ 60 years …

After decades of work, several interventions to prevent severe respiratory syncytial virus
(RSV) disease in high-risk infant and older adult populations have finally been approved …

Exacerbations of COPD are associated with worsening of the airflow obstruction,
hospitalisation, reduced quality of life, disease progression and death. At least 70% of …

Background Older adults with chronic cardiorespiratory or endocrine/metabolic conditions
are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness …

Respiratory syncytial virus (RSV) can lead to serious disease in infants, and no approved
RSV vaccine is available for infants. This first in-human clinical trial evaluated a single dose …